Traws Pharma TRAW Insider Ownership

Updated Oct 11, 2026

Across the past 12 months, open-market trades by Traws Pharma insiders were all purchases, totaling $998,207 (597.73K shares).

• Among Traws Pharma's insiders, Orbimed Advisors LLC (10% owner) was the largest open-market buyer over the past 12 months, purchasing $998,207 of stock (597.73K shares), most recently on April 16, 2026.
• Apart from open-market trades, TRAW insiders received 86.92K shares in stock awards in the past 12 months.
• Per Business Quant data, Traws Pharma insiders hold 1.99Mn shares in total based on their latest Form 4 filings, or 12.53% of the 15.86Mn shares outstanding; that total is unchanged from 1.99Mn shares at the end of Q2 2026.
• Indirect holdings, through trusts, partnerships, family members and other entities, make up 65.62% (1.3Mn shares) of Traws Pharma's insider total, with the other 34.38% (683.52K shares) held directly.
• The insider holdings in Traws Pharma belong to 10 insiders who have reported on Form 4 within the past two years.
• Traws Pharma's top three insider holders by shares held are Orbimed Advisors LLC (10% owner, 1.2Mn shares), Nikolay Savchuk (Chief Operating Officer, 251.83K shares) and Iain D. Dukes (Chief Executive Officer, 171.13K shares).
• Orbimed Advisors LLC alone accounts for 60.53% of the shares held by Traws Pharma insiders.
• Over the past 12 months, 11 insiders reported transactions in Traws Pharma stock in 39 Form 4 filings.
• The insider holdings and trades above for Traws Pharma reflect Form 4 filings through July 15, 2026.